CymaBay Therapeutics

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

CymaBay Therapeutics progresses in Phase 3 program, eyes commercial readiness

CymaBay Therapeutics is well-positioned with strong financials, a robust team, and a comprehensive approach to product launch and market access.
While facing challenges in regulatory engagement and competitive landscape, the company's focus on research, patient preferences, and global expansion provides opportunities for growth.
Anticipation for top-line data in Q3 2023 and a busy year ahead signal exciting prospects for CymaBay as they navigate towards potential commercial transformation.
Overall, CymaBay's strategic advancements, partnerships, and focus on patient outcomes position them favorably in the competitive landscape of PBC treatments.

CymaBay Therapeutics reports strong Phase 3 progress and financial stability

CymaBay Therapeutics showcased positive Phase 3 progress for seladelpar, backed by a strong financial position and a patient-centric approach to treatment advancement.
The company faces challenges in competitive positioning, resource allocation for post-marketing commitments, and meeting regulatory and patient expectations.
Opportunities lie in market expansion through partnerships, differentiation through clinical data, and enhancing treatment outcomes through ongoing studies.
Overall, CymaBay Therapeutics is poised for growth with a focus on advancing treatment guidelines, leveraging real-world data, and addressing unmet medical needs.

CymaBay reports strong Q2 earnings, faces reimbursement challenges ahead

CymaBay's Q2 2023 performance reflects financial strength and progress in seladelpar development, with upcoming milestone results expected.
While seladelpar shows promise in improving PBC patient quality of life, challenges in reimbursement criteria and rising expenses persist.
Opportunities lie in expanding patient reach through IDEAL study, exploring combination therapies, and transitioning patients into commercial use.

CymaBay excels in Q3 with seladelpar breakthrough therapy designation

CymaBay's Q3 2023 was marked by success in pivotal trials and financial strength, positioning seladelpar as a promising PBC treatment.
While facing challenges in expenses and regulatory concerns, CymaBay is leveraging opportunities in market expansion and differentiation.
The company's commitment to generating data and strategic pre-commercialization efforts underpin its confidence in seladelpar's potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.  Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update.

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.

CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

CymaBay caught a strong bid in early FY23 after advising its collaboration with Kaken Pharma in Japan. Its seladelpar compound has potential to create a medical breakthrough in primary biliary cholangitis.

CymaBay: Long Term Is Constructive With Potential Seladelpar Conversion

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $7.00 per share before underwriting discounts and commissions. In addition, CymaBay sold pre-funded warrants to purchase 2,142,857 shares of common stock in the offering, at a public offering price of $6.9999 per underlying share before underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants were offered by CymaBay. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share. The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by CymaBay. CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,821,428 shares of its common stock at the public offering price per share less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Alset EHome International

Fate Therapeutics

Hall of Fame Resort & Entertainment

Century Therapeutics

P3 Health Partners Inc

Avidity Biosciences

Summit Therapeutics

Trean Insurance Group

Viking Therapeutics

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Advances strategy to partner seladelpar for PBC outside U.S.

CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

100% technical buy signals. 13 new highs and up 84.95% in the last month.

CymaBay Therapeutics: Undiscovered Opportunity

CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - Chief Scientific Officer and President, R&D Dennis Kim - Chief Medical Officer Lewis Stuart - Chief Commercial Officer Dan Menold - Vice President, Finance Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Patrick Dolezal - LifeSci Capital Ed Arce - H.C. Wainwright & Co Mayank Mamtani - B.

CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call Transcript

Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2022 and to provide a business update.

CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4th – 8th).

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022

NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development.

CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that three abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4th – 8th).

CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022

CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CymaBay Therapeutics Inc. (CBAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock?

NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a mini symposium on primary biliary cholangitis (PBC) hosted by B. Riley Securities on Wednesday, August 24. The B. Riley healthcare equity research team will host the mini symposium titled “Orphan Liver Disease That May Not Be As Rare As You'd Think” that will feature fireside chats with leading PBC drug developers, alongside a PBC expert panel discussion, aimed at providing perspectives on the adoption and utilization of currently approved first line and second line therapies, as well as the anticipated evolution of the treatment paradigm over the coming years. The discussions will also focus on the field's latest thinking on the mid- to late-stage therapeutics pipeline, the state of surrogate endpoints, and appropriate target product profiles focused on driving patient-centric liver disease outcomes and quality of life benefits.

CymaBay Therapeutics to Participate in B. Riley's Mini PBC Symposium on August 24, 2022

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?

Cymabay Therapeutics, Inc. (NASDAQ:CBAY ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer & Corporate Secretary Sujal Shah - President, CEO & Director Charles McWherter - SVP & Chief Scientific Officer Daniel Menold - VP, Finance Lewis Stuart - Chief Commercial Officer Dennis Kim - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Steven Seedhouse - Raymond James & Associates Thomas Yip - H.C. Wainwright & Co. Mayank Mamtani - B.

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022

NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).

News for CymaBay Therapeutics Stock (CBAY)